PubMed:32936531
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 164-168 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T2 | 408-417 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
T3 | 422-432 | Body_part | denotes | chemokines | http://purl.org/sig/ont/fma/fma241981 |
T4 | 632-645 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
T5 | 800-808 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T6 | 998-1002 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 632-645 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 0-8 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 130-138 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T3 | 249-257 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T4 | 260-269 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T5 | 816-828 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T6 | 906-914 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 45-50 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T2 | 164-168 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T3 | 348-357 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signaling |
T4 | 490-495 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T5 | 517-522 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T6 | 523-526 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T7 | 607-617 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T8 | 632-645 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
T9 | 798-799 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 998-1002 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 62-64 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 66-81 | http://purl.obolibrary.org/obo/GO_0045087 | denotes | Innate immunity |
T2 | 275-297 | http://purl.obolibrary.org/obo/GO_0045087 | denotes | innate immune response |
T3 | 282-297 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
T4 | 348-366 | http://purl.obolibrary.org/obo/GO_0007165 | denotes | signaling pathways |
T5 | 348-357 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
T6 | 453-477 | http://purl.obolibrary.org/obo/GO_0002250 | denotes | adaptive immune response |
T7 | 462-477 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
T8 | 625-638 | http://purl.obolibrary.org/obo/GO_0045087 | denotes | innate immune |
T9 | 763-785 | http://purl.obolibrary.org/obo/GO_0045087 | denotes | innate immune response |
T10 | 770-785 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
T11 | 816-828 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T12 | 975-985 | http://purl.obolibrary.org/obo/GO_0065007 | denotes | regulation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-56 | Sentence | denotes | SARS-CoV-2 multifaceted interaction with the human host. |
T2 | 57-65 | Sentence | denotes | Part II: |
T3 | 66-125 | Sentence | denotes | Innate immunity response, immunopathology, and epigenetics. |
T4 | 126-229 | Sentence | denotes | The SARS-CoV-2 makes its way into the cell via the ACE2 receptor and the proteolytic action of TMPRSS2. |
T5 | 230-496 | Sentence | denotes | In response to the SARS-CoV-2 infection, the innate immune response is the first line of defense, triggering multiple signaling pathways to produce interferons, pro-inflammatory cytokines and chemokines, and initiating the adaptive immune response against the virus. |
T6 | 497-646 | Sentence | denotes | Unsurprisingly, the virus has developed strategies to evade detection, which can result in delayed, excessive activation of the innate immune system. |
T7 | 647-748 | Sentence | denotes | The response elicited by the host depends on multiple factors, including health status, age, and sex. |
T8 | 749-924 | Sentence | denotes | An overactive innate immune response can lead to a cytokine storm, inflammation, and vascular disruption, leading to the vast array of symptoms exhibited by COVID-19 patients. |
T9 | 925-1076 | Sentence | denotes | What is known about the expression and epigenetic regulation of the ACE2 gene and the various players in the host response are explored in this review. |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2 | 0-10 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3 | 45-50 | Species | denotes | human | Tax:9606 |
11 | 130-140 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
12 | 221-228 | Gene | denotes | TMPRSS2 | Gene:7113 |
13 | 249-269 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
14 | 816-828 | Disease | denotes | inflammation | MESH:D007249 |
15 | 906-914 | Disease | denotes | COVID-19 | MESH:C000657245 |
16 | 915-923 | Species | denotes | patients | Tax:9606 |
17 | 993-997 | Gene | denotes | ACE2 | Gene:59272 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 800-814 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-56 | Sentence | denotes | SARS-CoV-2 multifaceted interaction with the human host. |
T2 | 57-65 | Sentence | denotes | Part II: |
T3 | 66-125 | Sentence | denotes | Innate immunity response, immunopathology, and epigenetics. |
T4 | 126-229 | Sentence | denotes | The SARS-CoV-2 makes its way into the cell via the ACE2 receptor and the proteolytic action of TMPRSS2. |
T5 | 230-496 | Sentence | denotes | In response to the SARS-CoV-2 infection, the innate immune response is the first line of defense, triggering multiple signaling pathways to produce interferons, pro-inflammatory cytokines and chemokines, and initiating the adaptive immune response against the virus. |
T6 | 497-646 | Sentence | denotes | Unsurprisingly, the virus has developed strategies to evade detection, which can result in delayed, excessive activation of the innate immune system. |
T7 | 647-748 | Sentence | denotes | The response elicited by the host depends on multiple factors, including health status, age, and sex. |
T8 | 749-924 | Sentence | denotes | An overactive innate immune response can lead to a cytokine storm, inflammation, and vascular disruption, leading to the vast array of symptoms exhibited by COVID-19 patients. |
T9 | 925-1076 | Sentence | denotes | What is known about the expression and epigenetic regulation of the ACE2 gene and the various players in the host response are explored in this review. |
T1 | 0-56 | Sentence | denotes | SARS-CoV-2 multifaceted interaction with the human host. |
T2 | 57-65 | Sentence | denotes | Part II: |
T3 | 66-125 | Sentence | denotes | Innate immunity response, immunopathology, and epigenetics. |
T4 | 126-229 | Sentence | denotes | The SARS-CoV-2 makes its way into the cell via the ACE2 receptor and the proteolytic action of TMPRSS2. |
T5 | 230-496 | Sentence | denotes | In response to the SARS-CoV-2 infection, the innate immune response is the first line of defense, triggering multiple signaling pathways to produce interferons, pro-inflammatory cytokines and chemokines, and initiating the adaptive immune response against the virus. |
T6 | 497-646 | Sentence | denotes | Unsurprisingly, the virus has developed strategies to evade detection, which can result in delayed, excessive activation of the innate immune system. |
T7 | 647-748 | Sentence | denotes | The response elicited by the host depends on multiple factors, including health status, age, and sex. |
T8 | 749-924 | Sentence | denotes | An overactive innate immune response can lead to a cytokine storm, inflammation, and vascular disruption, leading to the vast array of symptoms exhibited by COVID-19 patients. |
T9 | 925-1076 | Sentence | denotes | What is known about the expression and epigenetic regulation of the ACE2 gene and the various players in the host response are explored in this review. |